Glycosaminoglycan Storage Disorders: a Review

Overview

Journal Biochem Res Int

Publisher Wiley

Specialty Biochemistry

Date 2011 Oct 21

PMID 22013531

Citations 61

Authors

Maria Francisca Coutinho

Lucia Lacerda

Sandra Alves

Affiliations

Soon will be listed here.

Abstract

Impaired degradation of glycosaminoglycans (GAGs) with consequent intralysosomal accumulation of undegraded products causes a group of lysosomal storage disorders known as mucopolysaccharidoses (MPSs). Characteristically, MPSs are recognized by increased excretion in urine of partially degraded GAGs which ultimately result in progressive cell, tissue, and organ dysfunction. There are eleven different enzymes involved in the stepwise degradation of GAGs. Deficiencies in each of those enzymes result in seven different MPSs, all sharing a series of clinical features, though in variable degrees. Usually MPS are characterized by a chronic and progressive course, with different degrees of severity. Typical symptoms include organomegaly, dysostosis multiplex, and coarse facies. Central nervous system, hearing, vision, and cardiovascular function may also be affected. Here, we provide an overview of the molecular basis, enzymatic defects, clinical manifestations, and diagnosis of each MPS, focusing also on the available animal models and describing potential perspectives of therapy for each one.

Citing Articles

mRNA Degradation as a Therapeutic Solution for Mucopolysaccharidosis Type IIIC: Use of Antisense Oligonucleotides to Promote Downregulation of Heparan Sulfate Synthesis.

Santos J, Goncalves M, Almeida M, Rocha H, Duarte A, Matos L Int J Mol Sci. 2025; 26(3).

PMID: 39941041 PMC: 11818647. DOI: 10.3390/ijms26031273.

Oral trehalose improves histological and behavior symptoms of mucopolysaccharidosis type II in iduronate 2-sulfatase deficient mice.

Lee H, Han J, Jeong R, Kang Y, Choi B, Kim S Sci Rep. 2025; 15(1):4882.

PMID: 39929944 PMC: 11811122. DOI: 10.1038/s41598-025-88362-0.

Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China.

Kang Q, Fang Y, Yang Y, Li D, Zheng L, Chen X Orphanet J Rare Dis. 2024; 19(1):324.

PMID: 39243096 PMC: 11378465. DOI: 10.1186/s13023-024-03333-4.

Structure of the human heparan-α-glucosaminide -acetyltransferase (HGSNAT).

Navratna V, Kumar A, Rana J, Mosalaganti S Elife. 2024; 13.

PMID: 39196614 PMC: 11357348. DOI: 10.7554/eLife.93510.

Multisystem Involvement in a Pediatric Patient With Suspected Mucopolysaccharidosis: A Case Report.

Sachani P, Dhande R, Parihar P, Bothara S, Kasat P Cureus. 2024; 16(5):e60593.

PMID: 38894766 PMC: 11184629. DOI: 10.7759/cureus.60593.

References

Csoka A, Frost G, Stern R . The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol. 2001; 20(8):499-508. DOI: 10.1016/s0945-053x(01)00172-x. View

Haskins M, Jezyk P, Desnick R, McDonough S, Patterson D . Alpha-L-iduronidase deficiency in a cat: a model of mucopolysaccharidosis I. Pediatr Res. 1979; 13(11):1294-7. DOI: 10.1203/00006450-197911000-00018. View

Tomatsu S, Montano A, Oikawa H, Smith M, Barrera L, Chinen Y . Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011; 12(6):931-45. DOI: 10.2174/138920111795542615. View

Clarke L, Wraith J, Beck M, Kolodny E, Pastores G, Muenzer J . Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009; 123(1):229-40. DOI: 10.1542/peds.2007-3847. View

Krivit W . Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol. 2004; 26(1-2):119-32. DOI: 10.1007/s00281-004-0166-2. View

Filippon L, Vanzin C, Biancini G, Pereira I, Manfredini V, Sitta A . Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. Mol Genet Metab. 2011; 103(2):121-7. DOI: 10.1016/j.ymgme.2011.02.016. View

Wraith J, Scarpa M, Beck M, Bodamer O, De Meirleir L, Guffon N . Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2007; 167(3):267-77. PMC: 2234442. DOI: 10.1007/s00431-007-0635-4. View

Scott H, Ashton L, Eyre H, Baker E, Brooks D, Callen D . Chromosomal localization of the human alpha-L-iduronidase gene (IDUA) to 4p16.3. Am J Hum Genet. 1990; 47(5):802-7. PMC: 1683689. View

Bosch A, Perret E, Desmaris N, Trono D, Heard J . Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther. 2000; 11(8):1139-50. DOI: 10.1089/10430340050015194. View

10.

Dickson P, Chen A . Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients. Curr Pharm Biotechnol. 2011; 12(6):946-55. DOI: 10.2174/138920111795542642. View

11.

Wraith J, Clarke L, Beck M, Kolodny E, Pastores G, Muenzer J . Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004; 144(5):581-8. DOI: 10.1016/j.jpeds.2004.01.046. View

12.

Wilson P, Suthers G, Callen D, Baker E, Nelson P, Cooper A . Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum Genet. 1991; 86(5):505-8. DOI: 10.1007/BF00194643. View

13.

Dziedzic D, Wegrzyn G, Jakobkiewicz-Banecka J . Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet. 2009; 18(2):200-5. PMC: 2987185. DOI: 10.1038/ejhg.2009.144. View

14.

Di Domenico C, Villani G, Di Napoli D, Nusco E, Cali G, Nitsch L . Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB. Am J Med Genet A. 2009; 149A(6):1209-18. DOI: 10.1002/ajmg.a.32861. View

15.

Yu W, Zhao K, Ryazantsev S, Rozengurt N, Neufeld E . Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B. Mol Genet Metab. 2001; 71(4):573-80. DOI: 10.1006/mgme.2000.3095. View

16.

Rodriguez A, Espejo A, Hernandez A, Velasquez O, Lizaraso L, Cordoba H . Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21. J Ind Microbiol Biotechnol. 2010; 37(11):1193-201. DOI: 10.1007/s10295-010-0766-x. View

17.

Karageorgos L, Brooks D, Pollard A, Melville E, Hein L, Clements P . Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat. 2007; 28(9):897-903. DOI: 10.1002/humu.20534. View

18.

Hanson M, Lupski J, Hicks J, Metry D . Association of dermal melanocytosis with lysosomal storage disease: clinical features and hypotheses regarding pathogenesis. Arch Dermatol. 2003; 139(7):916-20. DOI: 10.1001/archderm.139.7.916. View

19.

Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B . Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab. 2009; 99(1):10-7. DOI: 10.1016/j.ymgme.2009.08.008. View

20.

Shapiro J, Strome M, Crocker A . Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol. 1985; 94(5 Pt 1):458-61. DOI: 10.1177/000348948509400508. View